Mesenchymal tumor cells drive adaptive resistance of Trp53(−/−) breast tumor cells to inactivated mutant Kras

As precision medicine increases the response rate of treatment, tumors frequently bypass inhibition, and reoccur. In order for treatment to be effective long term, the mechanisms enabling treatment adaptation need to be understood. Here, we report a mouse model that, in the absence of p53 and the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: van Weele, Linda J., Djomehri, Sabra I., Cai, Shang, Antony, Jane, Sikandar, Shaheen S., Qian, Dalong, Ho, William H. D., West, Robert B., Scheeren, Ferenc A., Clarke, Michael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441006/
https://www.ncbi.nlm.nih.gov/pubmed/35398967
http://dx.doi.org/10.1002/1878-0261.13220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441006/
https://www.ncbi.nlm.nih.gov/pubmed/35398967
http://dx.doi.org/10.1002/1878-0261.13220

Ejemplares similares